PKG00284451.pdf

This file is an application guide instructing applicants on how to submit applications for the High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) funding opportunity (RFA-DA-25-060). Applicants must use either the General Instructions or the filtered Research Instructions for applications, with research-specific instructions identified separately. The guide directs users to the NIH's online application resources, including general and research-specific FORMS-H instruction documents available in HTML and PDF formats, and notes that application packages may contain optional forms requiring review of the funding opportunity and application instructions for submission requirements.

This guidance applies to the NIH's High Priority HIV and Substance Use Research opportunity, which supports innovative research at the intersection of HIV and substance use among people who use drugs (PWUD). The application deadline is March 5, 2027, with eligible applicants including higher education institutions, nonprofits, small businesses, tribal organizations, and various other entities. Applications must include a detailed research plan, preliminary data, and clear documentation of substance use nexus while aligning with NIH HIV/AIDS research priorities (NOT-OD-20-018). Funding is available under the Drug Abuse and Addiction Research Programs (CFDA 93.279), administered by the National Institute on Drug Abuse within the National Institutes of Health. Project periods typically do not exceed five years, with standard peer review timelines of 240-270 days from submission, or not exceeding 180 days for AIDS-related applications. Evaluation criteria include scientific and technical merit, research feasibility, potential contribution to addressing national drug abuse and HIV problems, and relevance to NIDA priorities.